Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus

Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus

Hepatitis B virus (HBV) infection, a global public health problem can be asymptomatic, acute or chronic and can lead to serious consequences of infection, including cirrhosis, and hepatocellular carcinoma. HBV, a partially double stranded DNA virus, belongs to the family Hepadnaviridae, and replicat...

Full description

Bibliographic Details
Main Authors:	Anna Kramvis, Evangelia-Georgia Kostaki, Angelos Hatzakis, Dimitrios Paraskevis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-10-01
Series:	Frontiers in Microbiology
Subjects:	genotypes subgenotypes tolerogen transmission HBeAg seroconversion
Online Access:	https://www.frontiersin.org/article/10.3389/fmicb.2018.02521/full

Similar Items

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Yan Gu, et al.
Published: (2024-01-01)

Study of hepatic histomorphology in HBeAg+ and HBeAg− patients with CHB: Experience from Bangladesh
by: Ayub Al Mamun, et al.
Published: (2013-01-01)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
by: Guangjun Song, et al.
Published: (2023-11-01)

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma
by: Kiyasha Padarath, et al.
Published: (2023-03-01)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
by: Ferruccio Bonino, et al.
Published: (2022-07-01)

Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
by: Su-Ru Lin, et al.
Published: (2021-06-01)

A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study
by: Ning Wang, et al.
Published: (2022-09-01)

HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation
by: Lorenzo Piermatteo, et al.
Published: (2021-09-01)

Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment
by: Jiezuan Yang, et al.
Published: (2020-07-01)

HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis
by: Xiaoyu Xie, et al.
Published: (2021-10-01)

What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?
by: Kadir Demir, et al.
Published: (2007-04-01)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
Published: (2006-01-01)

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
by: Weiqiang Gan, et al.
Published: (2020-12-01)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

Comparison of evolutionary patterns of different HBeAg status in HBV genotype B and C
by: Cai Ying, et al.
Published: (2015-12-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Low positivity rates for HBeAg and HBV DNA in rheumatoid arthritis patients: a case–control study
by: Yue Jia, et al.
Published: (2022-06-01)

Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by: Jianfei Long, et al.
Published: (2023-09-01)

Detection of Mutations in Precore and Basal Core Region in HBeAg Negative Chronic Hepatitis B Patients from Jaipur
by: Madhavi Vyas , Pratibha Sharma , Himanshu Sharma , Farah Deeba , Bharti Malhotra
Published: (2023-06-01)

Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by: Jianfei Long, et al.
Published: (2023-11-01)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
by: Zhan Zeng, et al.
Published: (2023-01-01)

Quantitative HBsAg and Qualitative HBeAg Predicts Intrauterine Placental Infection and Umbilical Blood Cord in Pregnant Women
by: Erry Gumilar Dachlan, et al.
Published: (2020-10-01)

Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes
by: Lu Xing, et al.
Published: (2022-09-01)

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
by: Fumitaka Suzuki, et al.
Published: (2021-12-01)

Evaluation of the Diagnostic Performances of the SD-Bioline<sup>®</sup>HBeAg Rapid Test Used Routinely for the Management of HBV-Infected Individuals in Burkina Faso
by: Abdoulaye Dera, et al.
Published: (2023-10-01)

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
by: Yifei Guo, et al.
Published: (2023-02-01)

Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase
by: Yuhua Gao, et al.
Published: (2024-04-01)

Status of Hepatitis Be Antigen in Chronic Hepatitis B Patients from Various Regions of Pakistan
by: Agha Babar Hussain
Published: (2017-09-01)

Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients
by: Yu Cui, et al.
Published: (2019-06-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01)

Coexistence of HBsAg/Anti-HBs and HBeAg/Anti-HBe in Sudanese Patients with Chronic Hepatitis B Virus Infection: A Cross-Sectional Study
by: Taqwa Hashim, et al.
Published: (2023-12-01)

Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients
by: Ran Hao, et al.
Published: (2019-01-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
by: Ying Yan, et al.
Published: (2022-11-01)

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment
by: Lisa Sandmann, et al.
Published: (2024-02-01)

The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection
by: Tsung-Yu Tsai, et al.
Published: (2018-07-01)

A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
by: Lu Zhang, et al.
Published: (2023-01-01)